Magnetic resonance imaging measurement of iron overload

Current Opinion in Hematology

Volumn 14, Issue 3, 2007, Pages 183-190

  Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Heart; Iron overload; Liver; Magnetic resonance imaging; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT;

CALIBRATION; CARDIOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DISEASE SEVERITY; DRUG MEGADOSE; FERRITIN BLOOD LEVEL; HEALTH CARE; HEPATOGRAPHY; HUMAN; IRON OVERLOAD; IRON THERAPY; LIVER BIOPSY; LIVER LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; QUANTUM MECHANICS; RADIOCARDIOGRAPHY; REPRODUCIBILITY; REVIEW; SICKLE CELL ANEMIA; STANDARD; THALASSEMIA MAJOR; TISSUE LEVEL; TREATMENT OUTCOME; VALIDATION PROCESS;

HUMANS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MYOCARDIUM;

EID: 34247159083     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3280d2b76b     Document Type: Review

References (72)

1. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101:15-19.
2. Gordeuk VR, Bacon BR, Brittenham GM. Iron overload: causes and consequences. Annu Rev Nutr 1987; 7:485-508.
3. McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci 1983; 19:205-266.
4. Ehlers KH, Levin AR, Markenson AL, et al. Longitudinal study of cardiac function in thalassemia major. Ann N Y Acad Sci 1980; 344:397-404.
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193.
6. Brissot P, Bourel M, Herry D, et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981; 80:557-565.
7. Bonkovsky HL, Slaker DP, Bills EB, Wolf DC. Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. Gastroenterology 1990; 99:1079-1091.
8. Borgna-Pignatti C, Castriota-Scanderbeg A. Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis. Haematologica 1991; 76:409-413.
9. de Virgiliis S, Sanna G, Cornacchia G, et al. Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. Arch Dis Child 1980; 55:43-45.
10. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81-85.
11. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38:57-62.
12. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739-761.
13. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:327-331.
14. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-573.
15. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110:971-977.
16. Emond MJ, Bronner MP, Carlson TH, et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999; 45:340-346.
17. Crisponi G, Ambu R, Cristiani F, et al. Does iron concentration in a liver needle biopsy accurately reflect hepatic iron burden in beta-thalassemia? Clin Chem 2000; 46:1185-1188.
18. Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005; 123:146-152.
19. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995; 89:757-761.
20. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118:96-98.
21. Ambu R, Crisponi G, Sciot R, et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol 1995; 23:544-549.
22. Villeneuve JP, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996; 25:172-177.
23. Nielsen P, Engelhardt R, Duerken M, et al. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci 2000; 23:257-258.
24. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic- susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671-1675.
25. Goldberg HI, Cann CE, Moss AA, et al. Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. Invest Radiol 1982; 17:375-380.
26. Howard JM, Ghent CN, Carey LS, et al. Diagnostic efficacy of hepatic computed tomography in the detection of body iron overload. Gastroenterology 1983; 84:209-215.
27. Chapman RW, Williams G, Bydder G, et al. Computed tomography for determining liver iron content in primary haemochromatosis. BMJ 1980; 280:440-442.
28. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106:1460-1465.
29. Gandon Y, Olivie D, Guyader D, et al. Noninvasive assessment of hepatic iron stores by MRI. Lancet 2004; 363:357-362.
30. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105:855-861.
31. Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging 2003; 18:616-620.
32. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18:33-39.
33. Tanner MA, He T, Westwood MA, et al. Multicenter validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006; 91:1388-1391. Demonstrates the intercenter reproducibility of cardiac T2*.
34. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171-2179.
35. Wood JC, Tyszka JM, Ghugre N, et al. Myocardial iron loading in transfusiondependent thalassemia and sickle-cell disease. Blood 2004; 103:1934-1936.
36. Wood JC, Enriquez C, Ghugre N, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci 2005; 1054:386-395.
37. Wood JC, Fassler J, Meade T. Mimicking liver iron overload using liposomal ferritin preparations. Mag Res Med 2004; 51:607-611.
38. Ghugre NR, Coates TD, Nelson MD, Wood JC. Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med 2005; 54:1185-1193.
39. Clark PR, St Pierre TG. Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic iron overload: a single spin-echo imaging methodology. Magn Reson Imaging 2000; 18:431-438.
40. Clark PR, Chua-anusorn W, St Pierre TG. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. Magn Reson Imaging 2003; 21:519-530.
41. Clark PR, Chua-Anusorn W, St Pierre TG. Proton transverse relaxation rate (R2) images of iron-loaded liver tissue: mapping local tissue iron concentrations with MRI. Magn Reson Med 2003; 49:572-575.
42. Clark PR, Chua-anusorn W, St Pierre TG. Reduction of respiratory motion artifacts in transverse relaxation rate (R2) images of the liver. Comput Med Imaging Graph 2004; 28:69-76.
43. Pardoe H, Clark PR, St Pierre TG, et al. A magnetic resonance imaging based method for measurement of tissue iron concentration in liver arterially embolized with ferrimagnetic particles designed for magnetic hyperthermia treatment of tumors. Magn Reson Imaging 2003; 21:483-488.
44. Alexopoulou E, Stripeli F, Baras P, et al. R2 relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patients. J Magn Reson Imaging 2006; 23:163-170. Liver biopsy validation of a multiecho R2 sequence in thalassemia patients.
45. Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004; 126:736-742.
46. Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005; 84:434-440.
47. Storey P, Thompson A, et al. R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging (in press).
48. Bulte JW, Miller GF, Vymazal J, et al. Hepatic hemosiderosis in nonhuman primates: quantification of liver iron using different field strengths. Magn Reson Med 1997; 37:530-536.
49. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca(2+) channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9:1187-1194.
50. Oudit GY, Trivieri MG, Khaper N, et al. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006; 84:349-364.
51. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127:348-355.
52. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8:543-547. Large, cross-sectional evaluation of the prevalence of left ventricular dysfunction as a function of cardiac T2*.
53. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival inmedically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574-578.
54. Anderson LJ, Westwood MA, Prescott E, et al. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006; 115:106-108.
55. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients: the importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30:219-227.
56. Brittenham GM, Nathan DG, Olivieri NF, et al. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361:183; author reply 183-184.
57. Fischer R, Engelhardt R. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361:182-183; author reply 183-184.
58. St Pierre TG, Chua-anusorn W, Webb J, et al. The form of iron oxide deposits in thalassemic tissues varies between different groups of patients: a comparison between Thai beta-thalassemia/hemoglobin E patients and Australian beta-thalassemia patients. Biochim Biophys Acta 1998; 1407:51-60.
59. Fitchett DH, Coltart DJ, Littler WA, et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14:719-724.
60. Olson LJ, Edwards WD, McCall JT, et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10:1239-1243.
61. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005; 112:535-543.
62. Wang ZJ, Lian L, Chen Q, et al. 1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. Radiology 2005; 234:749-755.
63. Ghugre NR, Enriquez CM, Gonzalez I, et al. MRI detects myocardial iron in the human heart. Magn Reson Med 2006; 56:681-686. Chemical validation of T2 and T2* in human tissue.
64. Westwood MA, Anderson LJ, Tanner MA, Pennell DJ. The relationship between myocardial iron deposition and left ventricular dysfunction in thalassemia using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005; 7:46-47.
65. Argyropoulou MI, Metafratzi Z, Kiortsis DN, et al. T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major. AJR Am J Roentgenol 2000; 175:1567-1569.
66. Sparacia G, Banco A, Midiri M, Iaia A. MR imaging technique for the diagnosis of pituitary iron overload in patients with transfusion-dependent beta-thalassemia major. AJNR Am J Neuroradiol 1998; 19:1905-1907.
67. Miszkiel KA, Paley MN, Wilkinson ID, et al. The measurement of R2, R2* and R2' in HIV-infected patients using the prime sequence as a measure of brain iron deposition. Magn Reson Imaging 1997; 15:1113-1119.
68. Graham JM, Paley MN, Grunewald RA, et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000; 123 (Pt 12):2423-2431.
69. Isokawa M, Kimura F, Matsuki T, et al. Evaluation of bone marrow iron by magnetic resonance imaging. Ann Hematol 1997; 74:269-274.
70. Drakonaki E, Papakonstantinou O, Maris T, et al. Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores. Eur Radiol 2005; 15:2462-2468.
71. Ooi GC, Khong PL, Chan GC, et al. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. Br J Haematol 2004; 124:385-390.
72. Ghugre NR, Enriquez CM, Coates TD, et al. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging 2006; 23:9-16. Good description of several important T2* processing details.